These experimental evidences, together with clinical studies demonstrating the association of resistin plasma levels with obesity [59, 60], metabolic syndrome (MetS) [61], and ischemic heart disease [62, 63], suggest that resistin might play a role in the interaction between insulin resistance, inflammation, and atherosclerosis [59, 60]. The gene discussed is RETN; the disease is metabolic syndrome.